Thus, these data indicate that IFN-I pathway is activated in tumor cells during CD47-SIRPα blockade treatment, and that tumor cell-intrinsic type I but not type II IFN signaling is essential for the therapeutic effect of CD47-SIRPα blockade therapy in mice. Here, CD47 is linked to neoplasm.